Our Senior Scientist, Kawanobe Ph.D., the first author, published in Nucleic Acid Therapeutics collaborative research with Axcelead Drug Discovery Partners, Inc. using XNAs technology.

On March 26, 2025, our Senior Scientist, Kawanobe Ph.D, the first author, announced the publication of new research findings in Nucleic Acid Therapeutics describing profiles of hepatotoxic reduction for XNAs technology.

This research is collaborative research with Axcelead Drug Discovery Partners, Inc.

■Title： Hepatotoxicity Reduction Profiles of Antisense Oligonucleotides Containing Amido-Bridged Nucleic Acid and 2′-O,4′-C-Spirocyclopropylene Bridged Nucleic Acid

Click below for more information.

(Kawanobe et al., Nucleic Acid Therapeutics, Published Online, 26 March 2025)